Study With Various Immunotherapy Treatments in Participants With Lung Cancer
This research study is for people with advanced non-small cell lung cancer. It's testing different combinations of new medicines, including ones called Domvanalimab, Quemliclustat, and Zimberelimab, sometimes with existing treatments like Docetaxel. The main aim is to find out how effective these new combinations are at shrinking or controlling the cancer (this is called the 'objective response rate'). Researchers also want to understand how safe these new treatments are and what side effects they might cause. By looking at these things, the study hopes to discover better treatment options for this kind of cancer.
En un coup d'œil
De quoi parle cette étude ?
This study is exploring potential new ways to treat a type of lung cancer called advanced non-small cell lung cancer. In this study, doctors are testing different combinations of new medications, often referred to as 'immunotherapy'. Immunotherapy works by helping your body's own immune system fight the cancer cells.
The study has a few main goals. Firstly, it wants to see how well these new combinations shrink the cancer or stop it from growing. This is important for understanding if the treatments are effective. Secondly, the researchers are carefully checking the safety of these new medicine combinations. They want to know what possible side effects might occur and how well people tolerate the treatments. This will help them understand if the treatments are not only effective but also manageable for patients.
By carefully studying these new combinations, the researchers hope to find more effective and safer treatment options for people living with advanced non-small cell lung cancer. This work is a step towards improving care and offering more choices for patients in the future.
Points clés
- This study evaluates new immunotherapy combinations for advanced lung cancer.
- It aims to find effective and safe new treatment options.
- Participation involves regular medical check-ups and monitoring.
- You might receive new treatments not yet widely available.
- Your health and safety are a top priority throughout the study.
Qui peut être éligible ?
To join this study, you would need to have advanced non-small cell lung cancer that has spread. Doctors would check that your general health is good enough for you to take part, and that the cancer can be measured. You would also need to be willing to provide a small sample of your tumour tissue for testing.
There are also some reasons why you might not be able to join. For example, if you have other serious health problems that the doctors think would make the study medicines unsafe for you. You also couldn't have had certain live vaccinations recently, or be taking high doses of steroid medications or other medicines that suppress your immune system just before starting the study. Certain autoimmune diseases might also prevent you from joining.
Cet étude pourrait-elle vous convenir ?
Répondez à ces questions rapides pour voir si vous êtes éligible. Ceci est un guide uniquement — l'équipe de recherche prend la décision finale.
- Do you have advanced non-small cell lung cancer that has spread?
- Is your general health good enough for you to take part?
- Do you have cancer that doctors can measure?
- Are you willing to provide a tumour tissue sample?
- Have you avoided live vaccines in the last 28 days?
- Are you taking any high-dose steroid or immune-suppressing medicines?
En quoi consiste la participation ?
If you decide to take part in this study, you would receive one of the new medicine combinations. You would have regular visits to the clinic for check-ups, where doctors would monitor your health and how the treatment is affecting you. This would include tests like blood samples and scans to see how your cancer is responding. The doctors and nurses would also ask about any side effects you might be experiencing. The exact number of visits and tests, and the total length of time you'd be in the study, would be explained to you in detail.
Risques et avantages potentiels
Locations (53)
- University of Alabama at Birmingham (UAB)Code postal vérifiéBirmingham, États-Unis
- University of California San Diego (UCSD)Code postal vérifiéLa Jolla, United States
- Memorial Cancer Institute at Memorial Regional HospitalCode postal vérifiéHollywood, États-Unis
- Hematology Oncology Associates Of The Treasure CoastCode postal vérifiéPort Saint Lucie, United States
- Florida Cancer Specialists (Administration and Drug Shipment)Code postal vérifiéThe Villages, United States
- Northwestern Memorial HospitalCode postal vérifiéChicago, États-Unis
- Ochsner Clinic FoundationCode postal vérifiéJefferson, United States
- Henry Ford HospitalCode postal vérifiéDetroit, United States
- Virginia Cancer Specialists, PCCode postal vérifiéFairfax, États-Unis
- Medical Oncology Associated, PS (dba Summit Cancer Centers)Code postal vérifiéSpokane, United States
- The Border Cancer HospitalCode postal vérifiéAlbury, Australia
- Pindara Private HospitalCode postal vérifiéBenowa, Australia
Questions fréquentes
What is non-small cell lung cancer?
It's the most common type of lung cancer, and 'advanced' means it has spread to other parts of the body.
Qu'est-ce que l'immunothérapie ?
Immunotherapy helps your body's own defence system fight cancer cells by boosting its ability to recognise and attack them.
What does a 'combination therapy' mean?
It means you'll be given more than one medicine at the same time, as they might work better together than alone.
Saurai-je quel traitement je reçois ?
The study design details this. You will be fully informed before deciding to take part.
What happens after the study ends?
This will be discussed with you, but your care will always be continued by your regular medical team.
Comment en savoir plus
Parlez toujours à votre médecin généraliste ou spécialiste avant de décider de participer à une étude.
Discussion
Discussion communautaire
Propulsé par notre forum à community.patient.info. Veuillez être respectueux — ceci n'est pas un avis médical.